Rigel Pharmaceuticals | RIGL - Dochód Netto





Dochód Netto Zmiana Data
Agenus USD 39.17M 49.8M 2026-03
Amgen USD 3.86B 1.49B 2026-09
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD -194.28M 61.55M 2026-06
AstraZeneca USD 3.12B 610M 2026-09
BioMarin Pharmaceutical USD -122.83M 167.59M 2026-09
Bristol-Myers Squibb USD 2.16B 1.16B 2026-09
Celldex Therapeutics USD -75.56M 2.05M 2026-09
Daiichi Sankyo JPY 82.9B 14.26B 2026-09
Eli Lilly USD 7.1B 301M 2026-06
Halozyme Therapeutics USD 247.05M 17.14M 2026-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -87M 27.65M 2026-09
Karyopharm Therapeutics USD -22.39M 79.81M 2026-03
Ligand Pharmaceuticals USD -28.48M 76.99M 2026-09
MacroGenics USD 19.52M 56.29M 2026-06
Neurocrine Biosciences USD 206.5M 62.1M 2026-09
Pfizer USD 3.24B 3.49B 2026-09
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Ultragenyx Pharmaceutical USD -118M 26M 2026-09
Veracyte USD 31.5M 6.01M 2026-09